Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL	B-cell neoplasm, Burkitt lymphoma, Carcinogenesis, Cell Transformation, Neoplastic, Chronic Disease, DNA Virus Infections, Disease Attributes, Epstein-Barr virus infection, Hemic and Lymphatic Diseases, Herpesviridae infectious disease, Infections, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Myeloproliferative Disorders, Neoplasms by Histologic Type, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Tumor Virus Infections, blast phase chronic myelogenous leukemia, BCR-ABL1 positive, bone marrow disorder, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, myeloid leukemia, neoplasm, precursor B-cell acute lymphoblastic leukemia, viral infectious disease	Recruiting	Phase 1	2025-11-05		NCT04260022

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Ascentage Pharma Group Inc.	30

9 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Augusta Cancer Center	Augusta	United States	1
City of Hope	Duarte	United States	238
Cleveland Clinic	Cleveland	United States	558
Fred Hutchinson Cancer Research Center	Seattle	United States	71
Princess Margaret Cancer Centre	Toronto	Canada	145
University of Alabama at Birmingham	Birmingham	United States	247
University of Maryland	Baltimore	United States	86
University of Texas MD Anderson Cancer Center	Houston	United States	192
Winship Cancer Institute, Emory University	Atlanta	United States	47